genOway Société anonyme ( ALGEN.PA) Stock. Should you Buy or Sell? $ 3.70
-0.13 (-3.50 %)
genOway Société anonyme Analysis
Updated on 10-09-2022
|52 Week Range
||$2.64 - $4.865
genOway Société anonyme opened the day at $3.70 which is -3.50 % on yesterday's close.
genOway Société anonyme has a 52 week high of $4.865 and 52 week low of $2.64, which is a difference of $2.225.
We like to see positive, upward trending shares, preferably with momentum.
Market capitalization is $30.32 M and total net profit is $14018969 which means the company is trading at 2.16 times profit to market capitalization. Theoretically, if you were to buy genOway Société anonyme for $30.32 M, it would take 15 years to get your money back. genOway Société anonyme are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
1 D | All
genOway Société anonyme Stock Forecast - Is genOway Société anonyme a Buy or Sell?
|DCF Score||Strong Buy|
|PE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin
Valuing genOway Société anonyme
|Price Book Value Ratio
||Price To Book Ratio
|Price To Sales Ratio
||Price Earnings Ratio
How liquid is genOway Société anonyme
||Debt Equity Ratio
|Long Term Debt To Capitalization
||Total Debt To Capitalization
Latest news about genOway Société anonyme
About genOway Société anonyme
CEO : Dr. Alexandre Fraichard
Sector : Healthcare
Industry : Biotechnology
Website : https://www.genoway.com
genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and immune checkpoint catalog cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was founded in 1999 and is headquartered in Lyon, France.